Application of nanoparticles in cancer therapy with an emphasis on cell cycle

被引：26
作者：
Almanghadim, Hossein Ghahramani [1 ]
Nourollahzadeh, Zahra [2 ]
Khademi, Nazanin Sadat [3 ]
Tezerjani, Masoud Dehghan [4 ]
Sehrig, Fatemeh Zeinali [1 ]
Estelami, Neda [1 ]
Shirvaliloo, Milad [5 ]
Sheervalilou, Roghayeh [6 ,7 ]
Sargazi, Saman [7 ]
机构：
[1] Islamic Azad Univ, Ahar Branch, Dept Mol Genet, Ahar, Iran
[2] Islamic Azad Univ, Ahar Branch, Dept Biol Sci, Ahar, Iran
[3] Shahid Beheshti Univ, Fac Biol Sci, Dept Genet, Tehran, Iran
[4] Shahid Sadoughi Univ Med Sci, Yazd Reprod Sci Inst, Abort Res Ctr, Yazd, Iran
[5] Tabriz Univ Med Sci, Infect & Trop Dis Res Ctr, Tabriz, Iran
[6] Zahedan Univ Med Sci, Pharmacol Res Ctr, Zahedan, Iran
[7] Zahedan Univ Med Sci, Resistant TB Inst, Cellular & Mol Res Ctr, Zahedan, Iran
来源：
CELL BIOLOGY INTERNATIONAL | 2021年 / 45卷 / 10期
关键词：
cancer therapy; cell cycle; nanoparticles (NPs); MITOCHONDRIA-MEDIATED APOPTOSIS; ZINC-OXIDE NANOPARTICLES; SILVER NANOPARTICLES; SELENIUM NANOPARTICLES; GOLD NANOPARTICLES; SILICA NANOPARTICLES; INDUCE APOPTOSIS; DNA-DAMAGE; IN-VITRO; HEPG2; CELLS;
D O I：
10.1002/cbin.11658
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Owing to their unique characteristics, nanoparticles (NPs) could be incorporated into valuable therapeutic modalities for different diseases; however, there are many concerns about risk factors in human applications. NPs carry therapeutic chemicals that could improve the outcome of cancer therapies. Nowadays, NPs are being recognized as important and strategic agents in treatment of several disorders due to their unique properties in targeting malignant cells in tumor sites. Numerous investigations have shown that the majority of chemotherapeutic agents can be modified through entrapment in submicron colloidal systems. Still, there are problems and limitations in application of NPs in cancer therapy. The aim of the present study is to focus on potential NPs usage in cancer treatment with an emphasis on the cell cycle of malignant cells.
引用
收藏
页码：1989 / 1998
页数：10
相关论文
共 103 条
[41]   The cell cycle [J].
Israels, ED ;
Israels, LG .
STEM CELLS, 2001, 19 (01) :88-91
[42]   Gold nanoparticles as novel agents for cancer therapy [J].
Jain, S. ;
Hirst, D. G. ;
O'Sullivan, J. M. .
BRITISH JOURNAL OF RADIOLOGY, 2012, 85 (1010) :101-113
[43]   Magnetic fluid hyperthermia (MFH):: Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles [J].
Jordan, A ;
Scholz, R ;
Wust, P ;
Fähling, H ;
Felix, R .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 1999, 201 :413-419
[44]   Nuclear Targeting of Gold Nanoparticles in Cancer Cells Induces DNA Damage, Causing Cytokinesis Arrest and Apoptosis [J].
Kang, Bin ;
Mackey, Megan A. ;
El-Sayed, Mostafa A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2010, 132 (05) :1517-+
[45]   DNA damage and cell cycle checkpoints [J].
Kaufmann, WK ;
Paules, RS .
FASEB JOURNAL, 1996, 10 (02) :238-247
[46]   Hyperthermia using nanoparticles - Promises and pitfalls [J].
Kaur, Punit ;
Aliru, Maureen L. ;
Chadha, Awalpreet S. ;
Asea, Alexzander ;
Krishnan, Sunil .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2016, 32 (01) :76-88
[47]   Nanoparticles: Properties, applications and toxicities [J].
Khan, Ibrahim ;
Saeed, Khalid ;
Khan, Idrees .
ARABIAN JOURNAL OF CHEMISTRY, 2019, 12 (07) :908-931
[48]   Synthesis and characterization of biocompatible ferrofluid based on magnetite nanoparticles and its effect on immunoglobulin G as an immune protein [J].
Khoramian, S. ;
Saeidifar, M. ;
Zamanian, A. ;
Saboury, A. A. .
JOURNAL OF MOLECULAR LIQUIDS, 2019, 273 :326-338
[49]   Therapeutic applications of selenium nanoparticles [J].
Khurana, Amit ;
Tekula, Sravani ;
Saifi, Mohd Aslam ;
Venkatesh, Pooladanda ;
Godugu, Chandraiah .
BIOMEDICINE & PHARMACOTHERAPY, 2019, 111 :802-812
[50]   Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells [J].
Kim, Tae Hee ;
Jin, Hua ;
Kim, Hyun Woo ;
Cho, Myung-Haing ;
Cho, Chong Su .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (07) :1723-1732
12345678910